Stocks charged higher in May, but it may take some time before investors know how much upside is left.
Summer can be a tricky season for the market. As many institutional investors step away from their screens for a bit, trading volumes thin out, making strong moves in either direction hard to take.... |
Good MorningU.S. stocks ended mostly higher Monday, with the S&P 500 and Nasdaq rebounding from Friday’s selloff as tech and chip stocks regained momentum. Sentiment improved after reports that Israel and Iran halted strikes, though oil still edged higher. Intel and Micron were among notable chip gainers as investors returned to AI-linked trades.
Apple unveiled its long-awaited AI-powered Siri overhaul and broader Apple Intelligence updates at WWDC, but shares slipped as investors appeared underwhelmed. AI infrastructure remained a major theme across the market, with headlines highlighting demand for memory, data centers and power solutions. Bank of America also warned of “red flags” in market breadth, noting the S&P 500 remains heavily concentrated in Big Tech.
In company news, Vail Resorts missed quarterly earnings and revenue estimates, while Mission Produce beat revenue estimates and announced a new buyback plan. Mama’s Creations beat earnings and revenue expectations. FedEx raised its dividend, AstraZeneca reported positive mid-stage weight-loss pill data, and Merck and Gilead discontinued a Phase 3 cancer-drug combination study. Featured: Inside a Former Merrill Lynch Advisor's Income Playbook (Ad) 
| Technology | |
Stocks charged higher in May, but it may take some time before investors know how much upside is left.
Summer can be a tricky season for the market. As many institutional investors step away from their screens for a bit, trading volumes thin out, making strong moves in either direction hard to take... Read the Full Story |
| From Our Partners | | One analyst believes AI stocks could face a sharp reversal as soon as tomorrow morning.
The concern: a downturn potentially more severe than the Dot-Com Bust, the 2008 financial crisis, and the Great Depression combined.
Anyone with exposure to AI stocks may want to take a closer look before markets open. | | Click here to see the one move to consider now |
| Industrials | |
Amprius Technologies (NYSE: AMPX) insiders are selling in 2026, but wouldn’t you? The stock is up more than 3,000% since its bottom in late 2024, when the company’s outlook was electrified, providing ample incentive, if not a need, to sell.
Insider portfolios are significantly skewed, need rebalanc... Read the Full Story |
| Materials | |
The U.S. dollar has fallen against other currencies during the second Trump administration, potentially driving up the cost of foreign goods amid other inflation-related pressures. While this may not help consumers already facing stretched pocketbooks, it can be a boon to investors, provided that t... Read the Full Story |
| From Our Partners | | China has slashed its U.S. Treasury holdings by more than 45% from their peak, while building gold vaults and payment networks that bypass the dollar entirely.
Since the Federal Reserve opened in 1913, the dollar has lost most of its purchasing power. Porter Stansberry argues a new monetary order is forming around AI infrastructure, chips and energy, pointing to stocks like Vertiv, GE Vernova and Arista Networks that have surged hundreds of percent in recent years. | | Watch Porter Stansberry's full interview and see his top pick now |
| Markets | |
With the S&P 500 pushing to higher and higher record levels in recent months, many investors are increasingly concerned about the bottom dropping out. Chasing momentum loses its appeal when valuations seem to be stretched uncomfortably thin. In this case, it may be more prudent to seek out targ... Read the Full Story |
| Materials | |
The rally in metals that seemed inevitable at the end of 2025 has taken a pause. That has some investors wondering if the shine has come off this trade. That might be a mistake. What’s happening in the sector today has more to do with shifting short-term priorities. The long game for gold, silver, ... Read the Full Story |
| From Our Partners | | The biggest IPO in history is likely just weeks away…
Anthropic, the company behind Claude AI, is rumoured to be lining up a Nasdaq debut before Thanksgiving… at a valuation of up to $2 trillion. But here’s what nobody’s talking about…
A raise of about $100 billion doesn’t just make headlines. It puts an enormous spotlight on the AI industry. And as investors rush to find the next big opportunity in artificial intelligence, some of the most interesting plays may be hiding outside traditional AI stocks. | | Click here to see my #1 pick for the Claude IPO. |
| Technology | |
Nebius Group (NASDAQ: NBIS) is up almost 175% year-to-date, and the momentum shows no signs of slowing. The AI infrastructure company has gone from strength to strength over the past year.
The stock closed at $227.81 on Thursday, not too far from its recent all-time high of $278.84, and the cataly... Read the Full Story |
| Communication Services | |
Technology stocks and the overall market took a meaningful hit on Friday. A strong jobs report triggered fears surrounding monetary policy, and shortly after, the selloff began. Broad rotation out of tech and into other areas of the market sent some of the sector's most prominent names lower in hea... Read the Full Story |
| Energy | |
The oil market has been making headlines, but the real story may not be geopolitical—it could be structural. As artificial intelligence drives unprecedented electricity demand, the companies keeping the grid running look increasingly like the best long-term energy plays available right now.
Marc Li... Read the Full Story |
| Finance | |
Big insurance companies often post big numbers—sometimes big in a good way, sometimes bad. Just ask Allstate (NYSE: ALL).
Less than four years after reporting massive losses, Allstate just delivered a powerful turnaround with strong underwriting, rising premiums, growing investment income, and a h... Read the Full Story |
| Consumer Discretionary | |
In Q1 2026, investment management behemoth Berkshire Hathaway (NYSE: BRK.B) made a portfolio decision that few saw coming. According to its 13F SEC filing, Berkshire took a new position in Macy’s (NYSE: M)—one of the United States' most iconic department stores.
While Macy’s has closed many locati... Read the Full Story |
| Tuesday's Early Bird Stock Of The Day Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; microscopes; protein consumables; industrial filtration products; and genomic medicines, such as custom nucleic acid products, plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX and SCIEX brands. The Diagnostics segment offers chemistry, immunoassay, microbiology, and automation systems; and molecular, acute care, and pathology diagnostics products. This segment also provides clinical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is based in Washington, the District of Columbia. | Should I Buy Danaher Stock? DHR Bull and Bear Case Explained
These insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of Danaher was last updated on Wednesday, October 21, 2026 at 6:37 PM.
Danaher Bull Case -
Danaher Co. recently reported third-quarter 2026 earnings that significantly exceeded expectations, with adjusted diluted earnings per share of $2.11, which beat the consensus estimate of $1.92 by approximately 9.9%, demonstrating strong profitability and operational execution.
-
The company raised its full-year 2026 adjusted earnings per share guidance to a range of $8.57 to $8.62, signaling management confidence in sustained growth and improved market conditions across its Biotechnology, Life Sciences, and Diagnostics segments.
-
Core revenue growth excluding respiratory testing accelerated to 5.5% in the third quarter, up 100 basis points from the second quarter, indicating a robust recovery in demand and effective commercial execution despite headwinds in specific product lines.
-
Danaher Co. generated $1.6 billion in free cash flow during the third quarter and $4 billion through the first nine months of the year, providing substantial liquidity for disciplined capital allocation, share buybacks, or further strategic investments.
-
The stock is currently trading at $233.99, which is near its 52-week high of $242.80, reflecting strong investor sentiment and a significant recovery from its 52-week low of $160.93, suggesting momentum and market confidence in the company's new strategic direction.
Danaher Bear Case -
Respiratory testing revenue created an approximately 250-basis-point headwind to core revenue growth in the third quarter, resulting in reported core revenue growth of only 3%, highlighting continued vulnerability and declining demand in this specific diagnostic area.
-
The company's price-to-earnings ratio stands at 41.56, which is relatively high and may limit upside potential if future earnings growth does not accelerate to justify the premium valuation, especially compared to historical averages.
-
Short interest increased by 7.49% in the most recent reporting period to 8,969,401 shares, indicating that a growing number of investors are betting against the stock, which could signal underlying concerns about the company's future performance or valuation.
-
Recent insider trading activity includes multiple sales by executives, such as Gregory M. Milosevich selling 1,320 shares in February 2026 and Brian W. Ellis selling 21,776 shares in November 2025, which may suggest that insiders are taking profits or have less confidence in near-term stock appreciation.
-
The company is undergoing a leadership transition with Julie Sawyer Montgomery as the new CEO, and while she has outlined strategic priorities, the market may be uncertain about the execution of her plan to become the "defining leader in Life Sciences and Diagnostics," creating potential volatility and risk.
| | View Today's Stock Pick |
|
| |
|
|
